{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:08:47Z","timestamp":1779912527078,"version":"3.53.1"},"reference-count":46,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/doi.org\/10.37349\/Open_Exploration_Crossmark_Policy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Aim: The interaction of concomitant benzodiazepine (BZD) exposure during immune checkpoint blockade has not been comprehensively investigated to date. This research aimed to determine the influence of BZD intake on the survival outcomes of patients with metastatic non-small-cell lung cancer (NSCLC) receiving pembrolizumab-based therapies.\nMethods: We included consecutive patients with advanced NSCLC who were given frontline pembrolizumab, whether as exclusive therapy or combined with platinum-based chemotherapy. The classification of BZD relied on the molecular composition, distinguishing between N-substituted and N-unsubstituted compounds.\nResults: During the time frame from April 2018 to May 2023, we enrolled 258 patients, 156 (60.5%) and 102 (39.5%) of whom received pembrolizumab alone or the combination regimen, respectively. We identified 108 (41.8%) exposed patients (BZD cohort) in comparison to all others (no-BZD cohort). After applying propensity-score matching, 108 cases were relevant for each cohort. After a median follow-up of 16.3 [95% confidence interval (CI) 13.1\u201319.7] months, univariate analysis revealed no significant differences in terms of progression-free survival (PFS) or overall survival (OS) between BZD cohorts. However, patients exposed to N-substituted compounds had significantly longer PFS and OS than those who did not take BZD. Conversely, patients exposed to N-unsubstituted compounds experienced significantly shortened OS. Multivariate testing showed that taking unspecified BZD had no impact on PFS or OS, while N-substituted BZD exposure correlated independently with longer PFS [hazard ratio (HR) 0.52 (95% CI 0.34\u20130.79); P = 0.002] and OS [HR 0.58 (95% CI 0.38\u20130.88); P &lt; 0.001]. In contrast, N-unsubstituted BZD intake had worsening effects on OS [HR 1.92 (95% CI 1.20\u20133.06); P = 0.006].\nConclusions: BZD exposure may impact the efficacy of immune checkpoint inhibitors in patients with advanced NSCLC. The specific composition may influence the choice among different compounds.<\/jats:p>","DOI":"10.37349\/etat.2025.1002287","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T06:36:39Z","timestamp":1737354999000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data"],"prefix":"10.37349","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7994-1371","authenticated-orcid":false,"given":"Fabrizio","family":"Nelli","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, Thoracic Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-0056","authenticated-orcid":false,"given":"Enzo Maria","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-9657","authenticated-orcid":false,"given":"Antonella","family":"Virtuoso","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Thoracic Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-1195","authenticated-orcid":false,"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1273-9905","authenticated-orcid":false,"given":"Armando","family":"Raso","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Thoracic and Interventional Radiology, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-584X","authenticated-orcid":false,"given":"Federica","family":"Natoni","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Molecular Biology and Genetics, Central Hospital of Belcolle, 0100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-4762","authenticated-orcid":false,"given":"Gloria","family":"Pessina","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Molecular Biology and Genetics, Central Hospital of Belcolle, 0100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9428-9207","authenticated-orcid":false,"given":"Daniele","family":"Remotti","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Pathology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Giovanni","family":"Chilelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4962","authenticated-orcid":false,"given":"Carlo","family":"Signorelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6343","authenticated-orcid":false,"given":"Agnese","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41:573\u201380. [PMID: 36917953 PMCID: PMC10202656 DOI: 10.1016\/j.ccell.2023.02.012]","DOI":"10.1016\/j.ccell.2023.02.012"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Li TJ, Jiang J, Tang YL, Liang XH. Insights into the leveraging of GABAergic signaling in cancer therapy. Cancer Med. 2023;12:14498\u2013510. [PMID: 37199392 PMCID: PMC10358225 DOI: 10.1002\/cam4.6102]","DOI":"10.1002\/cam4.6102"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yang Y, Ren L, Li W, Zhang Y, Zhang S, Ge B, et al. GABAergic signaling as a potential therapeutic target in cancers. Biomed Pharmacother. 2023;161:114410. [PMID: 36812710 DOI: 10.1016\/j.biopha.2023.114410]","DOI":"10.1016\/j.biopha.2023.114410"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Bhandage AK, Barragan A. GABAergic signaling by cells of the immune system: more the rule than the exception. Cell Mol Life Sci. 2021;78:5667\u201379. [PMID: 34152447 PMCID: PMC8316187 DOI: 10.1007\/s00018-021-03881-z]","DOI":"10.1007\/s00018-021-03881-z"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, et al. B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity. Nature. 2021;599:471\u20136. [PMID: 34732892 PMCID: PMC8599023 DOI: 10.1038\/s41586-021-04082-1]","DOI":"10.1038\/s41586-021-04082-1"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Huang D, Wang Y, Thompson JW, Yin T, Alexander PB, Qin D, et al. Cancer-cell-derived GABA promotes \u03b2-catenin-mediated tumour growth and immunosuppression. Nat Cell Biol. 2022;24:230\u201341. [PMID: 35145222 PMCID: PMC8852304 DOI: 10.1038\/s41556-021-00820-9]","DOI":"10.1038\/s41556-021-00820-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"M\u00f6hler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300:2\u20138. [PMID: 11752090 DOI: 10.1124\/jpet.300.1.2]","DOI":"10.1124\/jpet.300.1.2"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Nausea and Vomiting Related to Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version [Internet]. [Cited 2024 Sep 30]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nausea\/nausea-hp-pdq","DOI":"10.1007\/978-3-642-27233-2_6"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Yasuda S, Sugano K, Matsuda Y, Kako J, Takagi Y, Watanabe H, et al. Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer. Jpn J Clin Oncol. 2023;53:327\u201334. [PMID: 36636762 PMCID: PMC10064324 DOI: 10.1093\/jjco\/hyac206]","DOI":"10.1093\/jjco\/hyac206"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Olsen RW. GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology. 2018;136:10\u201322. [PMID: 29407219 PMCID: PMC6027637 DOI: 10.1016\/j.neuropharm.2018.01.036]","DOI":"10.1016\/j.neuropharm.2018.01.036"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Betlazar C, Middleton RJ, Banati R, Liu GJ. The Translocator Protein (TSPO) in Mitochondrial Bioenergetics and Immune Processes. Cells. 2020;9:512. [PMID: 32102369 PMCID: PMC7072813 DOI: 10.3390\/cells9020512]","DOI":"10.3390\/cells9020512"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Sparrow EL, James S, Hussain K, Beers SA, Cragg MS, Bogdanov YD. Activation of GABA(A) receptors inhibits T cell proliferation. PLoS One. 2021;16:e0251632. [PMID: 34014994 PMCID: PMC8136847 DOI: 10.1371\/journal.pone.0251632]","DOI":"10.1371\/journal.pone.0251632"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Falc\u00f3n CR, Hurst NF, Vivinetto AL, L\u00f3pez PHH, Zurita A, Gatti G, et al. Diazepam Impairs Innate and Adaptive Immune Responses and Ameliorates Experimental Autoimmune Encephalomyelitis. Front Immunol. 2021;12:682612. [PMID: 34354703 PMCID: PMC8329586 DOI: 10.3389\/fimmu.2021.682612]","DOI":"10.3389\/fimmu.2021.682612"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68:163\u201370. [PMID: 23220867 DOI: 10.1136\/thoraxjnl-2012-202374]","DOI":"10.1136\/thoraxjnl-2012-202374"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Oh TK, Park HY, Han JY, Song IA. Prior benzodiazepine use and mortality among adult patients with sepsis: A retrospective population-based cohort study in South Korea. Int J Clin Pract. 2021;75:e14517. [PMID: 34133821 DOI: 10.1111\/ijcp.14517]","DOI":"10.1111\/ijcp.14517"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022;185:576. [PMID: 35120665 DOI: 10.1016\/j.cell.2022.01.008]","DOI":"10.1016\/j.cell.2022.01.008"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol. 2021;11:617335. [PMID: 33777757 PMCID: PMC7992906 DOI: 10.3389\/fonc.2021.617335]","DOI":"10.3389\/fonc.2021.617335"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, et al. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Clin Cancer Res. 2023;29:3793\u2013812. [PMID: 37587561 PMCID: PMC10502465 DOI: 10.1158\/1078-0432.CCR-23-0547]","DOI":"10.1158\/1078-0432.ccr-23-0547"},{"key":"ref18","unstructured":"Registri farmaci sottoposti a monitoraggio [Internet]. Agenzia Italiana del Farmaco; c2024 [cited 2024 Sep 30]. Available from:  https:\/\/www.aifa.gov.it\/registri-farmaci-sottoposti-a-monitoraggio"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"PD-L1 IHC 22C3 pharmDx [Internet]. Agilent Technologies, Inc; c2024 [cited 2024 Sep 30]. Available from: https:\/\/www.agilent.com\/en\/product\/pharmdx\/pd-l1-ihc-22c3-pharmdx","DOI":"10.1016\/j.jtho.2016.11.1101"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4:351\u20137. [PMID: 29327044 PMCID: PMC5885829 DOI: 10.1001\/jamaoncol.2017.4771]","DOI":"10.1001\/jamaoncol.2017.4771"},{"key":"ref21","unstructured":"Benzodiazepine derivatives [Internet]. PharmGKB; c2024 [cited 2024 Sep 30]. Available from: https:\/\/www.pharmgkb.org\/chemical\/PA10402"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al.; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. [PMID: 28271869 PMCID: PMC5648544 DOI: 10.1016\/S1470-2045(17)30074-8]","DOI":"10.1016\/s1470-2045(17)30074-8"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wang X, Ji X. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies. Chest. 2020;158:S12\u201320. [PMID: 32658647 DOI: 10.1016\/j.chest.2020.03.010]","DOI":"10.1016\/j.chest.2020.03.010"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y; written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16. [PMID: 30788363 PMCID: PMC6351359 DOI: 10.21037\/atm.2018.12.10]","DOI":"10.21037\/atm.2018.12.10"},{"key":"ref25","unstructured":"The R project for statistical computing [Internet]. The R Foundation; c2024 [cited 2024 Sep 30]. Available from: https:\/\/www.r-project.org"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016;375:2293\u20137. [PMID: 27959688 DOI: 10.1056\/NEJMsb1609216]","DOI":"10.1056\/nejmsb1609216"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, St\u00fcrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149\u201356. [PMID: 16624967 PMCID: PMC1513192 DOI: 10.1093\/aje\/kwj149]","DOI":"10.1093\/aje\/kwj149"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Pizzutilo EG, Roman\u00f2 R, Roazzi L, Agostara AG, Oresti S, Zeppellini A, et al. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity. Cancer Res. 2023;83:2283\u201396. [PMID: 37205627 PMCID: PMC10345966 DOI: 10.1158\/0008-5472.CAN-23-0161]","DOI":"10.1158\/0008-5472.can-23-0161"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Chen J, Chen S, Luo H, Long S, Yang X, He W, et al. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review. Int Immunopharmacol. 2023;124:110919. [PMID: 37722262 DOI: 10.1016\/j.intimp.2023.110919]","DOI":"10.1016\/j.intimp.2023.110919"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Li H, Zhang L, Yang F, Zhao R, Li X, Li H. Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review. Front Immunol. 2023;14:1218386. [PMID: 37841249 PMCID: PMC10570520 DOI: 10.3389\/fimmu.2023.1218386]","DOI":"10.3389\/fimmu.2023.1218386"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, et al. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021;22:e57\u201362. [PMID: 32900613 PMCID: PMC7785632 DOI: 10.1016\/j.cllc.2020.07.016]","DOI":"10.1016\/j.cllc.2020.07.016"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Mont\u00e9gut L, Derosa L, Messaoudene M, Chen H, Lambertucci F, Routy B, et al. Benzodiazepines compromise the outcome of cancer immunotherapy. Oncoimmunology. 2024;13:2413719. [PMID: 39381589 PMCID: PMC11459736 DOI: 10.1080\/2162402X.2024.2413719]","DOI":"10.1080\/2162402x.2024.2413719"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Wiley SZ, Sriram K, Salmer\u00f3n C, Insel PA. GPR68: An Emerging Drug Target in Cancer. Int J Mol Sci. 2019;20:559. [PMID: 30696114 PMCID: PMC6386835 DOI: 10.3390\/ijms20030559]","DOI":"10.3390\/ijms20030559"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"O\u2019Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014;27:126\u201335. [PMID: 24508914 PMCID: PMC4021379 DOI: 10.1016\/j.ceb.2014.01.005]","DOI":"10.1016\/j.ceb.2014.01.005"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lynch JR, Wang JY. G Protein-Coupled Receptor Signaling in Stem Cells and Cancer. Int J Mol Sci. 2016;17:707. [PMID: 27187360 PMCID: PMC4881529 DOI: 10.3390\/ijms17050707]","DOI":"10.3390\/ijms17050707"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Xu J, Mathur J, Vessi\u00e8res E, Hammack S, Nonomura K, Favre J, et al. GPR68 Senses Flow and Is Essential for Vascular Physiology. Cell. 2018;173:762\u201375.e16. [PMID: 29677517 PMCID: PMC5951615 DOI: 10.1016\/j.cell.2018.03.076]","DOI":"10.1016\/j.cell.2018.03.076"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Cao L, Li W, Yang X, Zhang W, Li M, Zhang H, et al. Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment. Cancer Gene Ther. 2021;28:1213\u201324. [PMID: 34158625 PMCID: PMC8571096 DOI: 10.1038\/s41417-021-00354-0]","DOI":"10.1038\/s41417-021-00354-0"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Ye S, Zhu Y, Zhong D, Song X, Li J, Xiao F, et al. G protein-coupled receptor GPR68 inhibits lymphocyte infiltration and contributes to gender-dependent melanoma growth. Front Oncol. 2023;13:1202750. [PMID: 37350933 PMCID: PMC10282648 DOI: 10.3389\/fonc.2023.1202750]","DOI":"10.3389\/fonc.2023.1202750"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, et al. Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023;11:e007310. [PMID: 37852738 PMCID: PMC10603340 DOI: 10.1136\/jitc-2023-007310]","DOI":"10.1136\/jitc-2023-007310"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4:100878. [PMID: 36599350 PMCID: PMC9873827 DOI: 10.1016\/j.xcrm.2022.100878]","DOI":"10.1016\/j.xcrm.2022.100878"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40:509\u201323.e6. [PMID: 35537412 PMCID: PMC9221568 DOI: 10.1016\/j.ccell.2022.04.004]","DOI":"10.1016\/j.annonc.2021.10.090"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther. 2010;9:2430\u20139. [PMID: 20682658 DOI: 10.1158\/1535-7163.MCT-10-0258]","DOI":"10.1158\/1535-7163.mct-10-0258"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kiss E, Abdelwahab EHMM, Steib A, Papp E, Torok Z, Jakab L, et al. Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner. Respir Res. 2020;21:120. [PMID: 32434541 PMCID: PMC7238555 DOI: 10.1186\/s12931-020-01389-x]","DOI":"10.1186\/s12931-020-01389-x"},{"key":"ref44","unstructured":"Cao P, Wang Y. Effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with EGFR-TKI resistant moderate and advanced lung cancer. Am J Transl Res. 2021;13:7857\u201365. [PMID: 34377263 PMCID: PMC8340177]"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25:94\u2013102. [PMID: 14698135 DOI: 10.1016\/j.cyto.2003.10.004]","DOI":"10.1016\/j.cyto.2003.10.004"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T06:36:49Z","timestamp":1737355009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":46,"URL":"https:\/\/doi.org\/10.37349\/etat.2025.1002287","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-1-6","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-1-20","order":2,"name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002287"}}